Determinants and outcomes of access related blood-stream infections among Irish haemodialysis patients; a cohort study by Mohamed, Husham et al.
RESEARCH ARTICLE Open Access
Determinants and outcomes of access-
related blood-stream infections among Irish
haemodialysis patients; a cohort study
Husham Mohamed1,2, Alaa Ali1,2, Leonard D. Browne2, Nuala H. O’Connell2,3, Liam Casserly1,2,
Austin G. Stack1,2,4* and Wael F. Hussein1,2
Abstract
Background: Infections are the second leading cause of death and hospitalisation among haemodialysis (HD)
patients. Rates of access-related bloodstream infections (AR-BSI) are influenced by patient characteristics and local
protocols. We explored factors associated with AR-BSI in a contemporary cohort of HD patients at a tertiary
nephrology centre.
Methods: A retrospective cohort of 235 chronic HD patients was identified from a regional dialysis programme between
Jan 2015 and Dec 2016. Data on demographics, primary renal disease, comorbid conditions and dialysis access type were
obtained from the Kidney Disease Clinical Patient Management System (KDCPMS). Data on blood cultures were captured
from the microbiology laboratory. Poisson regression with robust variance estimates was used to compare infection rates
and relative risk of AR-BSI according to the site and type of vascular access.
Results: The mean age was 65 (± 15) years, 77% were men, and the median follow up was 19 months (IQR: 10–24
months), accumulating 2030 catheter-months and 1831 fistula-months. Overall rates of AR-BSI were significantly
higher for central venous catheter (CVC) compared to arteriovenous fistula (AVF), (2.22, 95% (CI): 1.62–2.97) versus 0.11
(0.01–0.39) per 100 patient-months respectively), with a rate ratio of 20.29 (4.92–83.66), p < 0.0001. This pattern
persisted across age, gender and diabetes subgroups. Within the CVC subgroup, presence of a femoral CVC
access was associated with significantly higher rates of AR-BSI (adjusted RR 4.93, 95% CI: 2.69–9.01). Older age
(75+ versus < 75 years) was not associated with significant differences in rates of AR-BSI in the unadjusted or
the adjusted analysis. Coagulase negative Staphylococcus (61%) and Staphylococcus aureus (23%) were the
predominant culprits. AR-BSIs resulted in access loss and hospitalisation in 57 and 72% of events respectively,
and two patients died with concurrent AR-BSI.
Conclusions: Rates of AR-BSI are substantially higher in CVC than AVF in contemporary HD despite advances
in catheter design and anti-infective protocols. This pattern was consistent in all subgroups. The policy of AVF
preference over CVC should continue to minimise patient morbidity while at the same time improving anti-
infective strategies through better care protocols and infection surveillance.
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Background
Patients on haemodialysis (HD) endure infection rates
that are more than 26 times higher than that of the
general population [1], and more than 100 to 200-fold
higher for specific organisms [2]. They are the second
leading cause of hospitalisation and mortality in the
dialysis population [3–5]. National and international
guidelines along with national policy initiatives [6–9]
recommend the use of arteriovenous fistula (AVF) when-
ever possible, as the risk of infections and other compli-
cations is highest among patients using central venous
catheters (CVCs) [3, 10, 11]. Despite the dangers associ-
ated with CVC use, these devices remain the principal
type of access in the majority of HD patients in Ireland
[12, 13] and internationally [14].
The alarmingly high rates of access-related blood-
stream infections (AR-BSI) in patients undergoing dialy-
sis with a CVC has forced changes in clinical practices
that include better anti-infective protocols, increasing
adoption of catheter lock solutions, and better anti-
microbial surveillance protocols in order to reduce
CVC-related infection rates [15–18]. It is unclear, how-
ever, to what extent these changes have curbed the high
rates of AR-BSI in the context of an increasing elderly
HD phenotype with a high burden of complex health
problems. It is also uncertain whether any benefit de-
rived from these measures extends to very high-risk
groups especially the elderly, patients with diabetes and
those dialysed with a femoral CVC. While the formation
of a functioning AVF is the preferred vascular access,
this is not easily attainable in all individuals, especially
elderly patients on HD [19]. Furthermore it remains
controversial whether CVCs are superior to AVFs
among elderly patients undergoing dialysis with a re-
cent study finding lower rates of catheter-related bac-
teraemia in elderly patients compared to younger
patients [18, 20–22].
Within the Irish health system, data is lacking on the
on the frequency and impact of AR-BSI in HD. The
availability of such data along with clinical outcomes will
help inform healthcare providers and policy-decision
makers on access type, and will drive quality improve-
ment initiatives to improve patient outcomes. We deter-
mined the rates of AR-BSI in a contemporary cohort of
HD patients dialysed with a CVC or AVF and explored
the relative contribution of demographic and clinical fac-
tors to overall rates of AR-BSI.
Methods
Study design and setting
We conducted a retrospective observational study to ex-
plore AR-BSI in a contemporary cohort of HD patients.
We identified all adult patients receiving chronic HD
during 2015 and 2016 under the care of a tertiary
nephrology centre. Patients were observed from the first
to the last dialysis they received during the period be-
tween 1/1/2015 and 31/12/2016. Primary access type
and changes from CVC to AVF or vice versa during the
observation period were recorded. All AR-BSI events
were captured during the observation period and out-
comes of these events were recorded. The rates of BSIs
were calculated using standard definitions described
below. As this study aimed to examine rates of bacter-
aemia associated with access types used over prolonged
periods of time in outpatient settings, temporary dialysis
catheters were not included in the analysis.
Description of local practice
Patients received dialysis at a unit attached to the main
hospital or at an affiliated outpatient dialysis unit. All
tunnelled CVCs were inserted by interventional radiolo-
gists. CVC type used is ProGuide™, produced by Merit
Medical Systems®. An access care bundle was in place to
reduce risk of infection. This included protocols for
hand hygiene and use of protective equipment during
connection and disconnection of dialysis lines. BioPatch®
(Ethicon©) dressings were applied to the exit site, and
were changed on a weekly basis. Catheters were locked
with 46.7% citrate. Disposable catheter hubs were used.
Before connection, catheter hubs and fistula needle in-
sertion sites were decontaminated with 10% iodinated
povidone. When an access infection was suspected, two
sets of blood cultures were taken from each port of a
catheter or from a peripheral vessel in case of a fistula.
Empiric antimicrobial therapy was commenced when
there was strong clinical suspicion after collection of cul-
ture samples. Dialysis catheters were removed if the
causative organism was Staphylococcus aureus, fungal,
or if the infection is difficult to clear. The HD unit
protocol mandates regular screening for methicillin-
resistant S. aureus (MRSA), vancomycin-resistant En-
terococcus species (VRE), extended spectrum beta
lactamase (ESBL)- producing organisms and carbapenem-
resistant Enterobacteriaceae (CRE). Colonization with
MRSA is treated with mupirocin nasal disinfection and
chlorhexidine wash for skin disinfection followed by
rescreening. All patients colonized with MRSA or CRE re-
ceive dialysis in isolation rooms. All inpatient and out-
patient microbiology samples from the healthcare region
are sent to a single central microbiology laboratory located
within the main hospital.
Participants and data sources
Patients were identified using data from the Kidney Disease
Clinical Patient Management System (KDCPMS), a national
multi-domain electronic health record system that tracks
clinical care of HD patients in the Irish health system.
Patients who received acute dialysis or holiday dialysis
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treatments were excluded. Study entry age, access
type and access site were defined for each patient at
the date of first dialysis during the study period.
Baseline data were captured on age, sex, primary
cause of End Stage Kidney Disease (ESKD), comorbid
conditions, the type and site of the dialysis access.
Blood culture results from patients during the obser-
vation period were retrieved from the microbiology
laboratory database. All changes in dialysis access
type and site were recorded during the study period.
Access site was recorded as upper extremity or fem-
oral location. The internal jugular vein (IJ) was the
most common access at the centre, with subclavian
access only reserved for situations where IJ access
was not attainable. Due to the small number of non-IJ
sites, comparisons between different non-femoral CVC’s
was not reliable or informative. The determination of in-
fection rates and rate ratios was based on the current ac-
cess in use at time of infection.
Definition of AR-BSI and calculation of rates
Access-related bloodstream infection (AR-BSI) was
defined as growth of a typical organism with either a
documented exit site or tunnel infection, or with no
other identified source of infection. Patients with
atypical organisms who received antimicrobial treat-
ment for 2 weeks or more were also considered to
have AR-BSI. Blood cultures that were positive with
the same organism within 21 days of a previous posi-
tive culture were considered part of the initial event
and not counted as a separate event. The definition
of AR-BSI in our study did not include sampling
from a peripheral vein (as recommended by CDC),
however, previous reports suggest that peripheral
blood culture results add little to the sensitivity and
specificity of cultures blood obtained from the HD
circuit and the venous catheter hub [23].
We followed guidelines issued by the Centers for
Disease Control and Prevention (CDC) – National
Healthcare Safety Network (NHSN) for calculation of
event rates [24, 25]. The number of chronic HD pa-
tients under the care of the tertiary centre on the
first day of each month was used as the denominator
for that month. Vascular access type at the start of
the month was used to identify subgroups for cath-
eter patient-months and fistula patient-months. The
numerator for AR-BSI event rates for each month
was the number of identified AR-BSI events during
that month. All recorded CVCs were tunnelled cathe-
ters (none were temporary dialysis catheters). Only
two arteriovenous grafts were in use during the ob-
servation period. For the purposes of this analysis,
these were grouped with AVF.
Ethical approval
Ethical approval was not sought this study as the surveil-
lance of infections in dialysis patients is part of regular
clinical audit and the hospital’s quality improvement
programme [26].
Statistical analysis
Baseline characteristics were presented for the whole
group and for subgroups of study entry access type.
Continuous variables were presented as mean ± standard
deviations and categorical variables were presented as
percentages. Comparisons between groups according to
vascular access type were performed by analysis of vari-
ance for continuous variables and Chi-square test for
categorical variables.
Poisson regression employing the Huber-White sand-
wich variance estimator was used to compare the infec-
tion rates and determine the risk of infection according
to vascular access type. Rates of AR-BSI were presented
as events per 100 patient-months with robust 95% confi-
dence intervals (CIs). To determine factors associated
with bacteraemia among patients using CVC, univariable
and multivariable models were constructed to examine
the association of demographic and clinical factors, and
access insertion site with the risk of AR-BSI. Model de-
velopment progressed using a manual strategy taking
into consideration known associations from published
literature, and statistical significant univariable associa-
tions. A final model was constructed to determine the
association of age, sex, diabetes, and access type with the
outcome of AR-BSI in patients receiving dialysis by
CVC. Goodness of fit was assessed using the Pearson
and Deviance statistics. All analyses were conducted
using R version 3.4.
Results
Baseline characteristics of study population
A total of 281 adult patients received dialysis between 1/
1/2015 and 31/12/2016. Of those, 46 were excluded
(Acute HD: 26, Visitor/Holiday HD: 20) leaving 235 pa-
tients eligible for inclusion in the final study sample.
During the observation period, the monthly census in-
creased from 134 patients to 181 from Jan 2015 to Dec
2016, and the percentage of patients receiving dialysis by
CVC ranged from 48 to 57% (Additional file 1:
Table S1). Median patient follow up was 19 months
(IQR: 10–24months) resulting in 3861 patient months of
observation, 2030 catheter-months and 1831 fistula-
months (Additional file 1: Table S2). There were 74 blood-
stream infections detected during the observation period,
of which 47 were related to HD access (Fig. 1).
Table 1 illustrates the baseline characteristics of partic-
ipants at study entry. The average age was 65 (± 15)
years, 28.5% were 75 years of age or older, and the
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majority were men (77%). Diabetes was the most com-
mon cause of ESKD, while hypertension and diabetes
were the most prevalent recorded comorbid conditions.
The distribution of baseline characteristics was similar
for patients dialysed by either AVF or CVC with the ex-
ception of sex and primary cause of ESKD. The CVC
group had significantly higher proportion of women and
fewer patients who had diabetes, hypertension and renal
cystic disease as their primary cause of renal disease.
The baseline characteristics of patients dialysed through
a CVC is shown in Table 2. Patients age ≥ 75 years had
significantly more hypertension and congestive heart fail-
ure than younger counterparts while the distribution of
other characteristics was similar. Distribution of baseline
characteristics in the whole group (any access) by age
group is shown in Additional file 1: Table S3.
Rates of access-related bloodstream infection (AR-BSI) in
CVC versus AVF
The rate of AR-BSI in patients dialysed with a CVC was
significantly higher than in patients with an AVF [2.22
(95% 1.62–2.97) versus 0.11 (95% CI: 0.01–0.39) per 100
patient months respectively, p < 0.001], with an un-
adjusted incidence rate ratio of 20.29 (95% CI 4.92–
83.66) as shown in Fig. 2. Among all specified subgroups
of age, sex, diabetes and access site, the incidence rates
of AR-BSIs were significantly and substantially higher
among those using a CVC compared to AVF.
By far the highest rate of AR-BSI was observed with a
femoral CVC access, 8.50 (95% CI 4.52–14.53) events
per 100 patient months. Among patients receiving dialy-
sis by tunnelled catheter, the rate ratio of AR-BSI for
femoral versus non-femoral CVC was 4.98 (95% CI
2.71–9.15), p < 0.001. In multivariable analysis adjusting
for age, sex, and diabetes, use of a femoral CVC was as-
sociated with 4.93 times (95% CI 2.69–9.01) the risk of
infection compared to a non-femoral CVC site – Fig. 3.
Fig. 1 Study flow diagram
Table 1 Baseline characteristics of the total population
Overall
n = 235❖
AVF/AVG at study
entry❖ n = 96
CVC at study
entry❖ n = 139
Femoral access 4.3 2.1 5.8
Age in years (mean (SD)) 65 (15) 66 (14) 64 (15)
Age groups
< 75 years 71.5 69.8 72.7
75 + 28.5 30.2 27.3
Women* 33.2 22.9 40.3
Primary cause of renal disease*
Diabetes mellitus 23.8 27.1 21.6
Glomerulonephritis 19.6 19.8 19.4
Cystic kidney disease 8.1 13.5 4.3
Other urologic 6.4 6.2 6.5
Hypertension 3.8 6.2 2.2
Other cause 16.2 11.5 19.4
Unknown/missing 22.1 15.6 26.6
Comorbidities
Hypertension 68.9 67.7 69.8
Diabetes 35.3 33.3 36.7
Atherosclerotic
heart disease
24.3 26.0 23.0
Congestive
heart failure
15.7 15.6 15.8
Other cardiac 22.1 25.0 20.1
Cerebrovascular
disease
11.9 13.5 10.8
Peripheral vascular
disease
8.5 7.3 9.4
❖Column % unless specified otherwise
*p < 0.05
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There were no significant differences in the rates of
AR-BSI by age (75+ versus < 75 years) in the unadjusted
or the adjusted analyses.
Type of organism
The distribution of organisms isolated from blood cul-
tures is shown in Table 3. The most common isolates
were Staphylococci identified in 85% of positive blood
cultures. The majority of these were Coagulase-negative
Staphylococcal (CoNS) infections with S. aureus contrib-
uting 23.4%. No fungal infections were recorded during
the study period.
AR-BSI outcomes
AR-BSIs resulted in hospitalisation and access loss in 34
(72%) and 27 (57%) of the events respectively. Two pa-
tients died with AR-BSI events; one with poly-microbial
infection.
Sensitivity analysis
To address whether a number of individuals prone to
risk in the CVC group may be leading to an exagger-
ation of risk, we conducted a sensitivity analysis by
excluding patients with more than 1 and more than 2
recorded CRBSIs (Catheter-Related Bloodstream Infec-
tions). No variables were found to be statistically signifi-
cant when excluding patients with more than 1 case of
CBRSI (n = 10). However, excluding patients with more
than two cases (n = 2) yielded similar results to that of
the primary analysis. The median duration between
CRBSI’s among these patients was 117 days with a mini-
mum of 50 days and a maximum of 465 days between
events. There were a few patients with recurrent infec-
tions (more than 2 cases of CBRSIs) in this study and
omission of these patients did not alter the primary find-
ings of this study.
Discussion
In this large centre-based study, we emphasise the sig-
nificant risk of bloodstream infections associated with
use of tunnelled dialysis catheters. Compared to patients
who were using an AVF, patients with a CVC experi-
enced a 20-fold higher risk of access-related bacter-
aemia. The risk associated with CVC use was
independent of age and comorbid disease measured at
baseline. Subgroup analysis confirmed that the pattern
of risk from CVC was present in younger and in older
patients, men and women, and in patients with and
without diabetes. These results would suggest that des-
pite advances in anti-infective protocols, innovative cath-
eter designs, and the implementation of national
guidelines, CVCs remain a major source of serious mor-
bidity in HD patients.
The adverse impact of CVC over AVF on catheter-
related bacteraemia rates was overwhelmingly apparent
from this analysis. Our observed rates of AR-BSI events
were 2.22 and 0.11 events per 100 patient-months for
CVC and AVF respectively, a 20-fold difference. Our
findings are concordant with reports from other parts of
the world. AR-BSI rates in patients with CVC and AVF
were 3.1 and 0.6, and 3.5 and 1.7 per 100 patient-
months from Greece and Brazil respectively [4, 18]. A
study from the National Healthcare Safety Network
(NHSN) in the US reported pooled rates of 2.55 and
0.23 events per 100 patient-months for CVC and AVF
respectively from 2007 and 2011 [27], while a more re-
cent report suggested improvements with estimates of
1.83 and 0.16 for CVCs and AVF respectively [24]. The
patient-months distribution in this last report was 19%
for CVC and 63% for AVF, reflecting a much lower de-
pendence on tunnelled catheters than in our Irish co-
hort. The rates of AR-BSI in our cohort compare
favourably with those from the CDC report in the US
[24] in that rates were at the 50th percentile for
CVC-related BSIs, and below the 25th for AVF-related
infections. Despite these reassuring statistics, there is
emerging evidence that further improvements are
Table 2 Baseline characteristics by age group among patients
with a tunnelled central venous catheter at study entry
Characteristic All patients ❖
(n = 139)
Age groups (years)❖
< 75 (n = 101) 75+ (n = 38)
Femoral access 5.8 5.9 5.3
Age in years (mean (SD))* 64 (15) 57 (12) 82 (5)
Female 40.3 38.6 44.7
Primary cause of renal disease
Diabetes mellitus 21.6 20.8 18.4
Glomerulonephritis 19.4 19.8 18.4
Cystic kidney disease 4.3 5.0 2.6
Other urologic 6.5 6.9 5.3
Hypertension 2.2 3.0 0.0
Other cause 19.4 19.8 18.4
Unknown/missing 26.6 24.8 31.6
Comorbidities
Hypertension* 69.8 62.4 89.5
Diabetes 36.7 34.7 42.1
Atherosclerotic
heart disease
23.0 18.8 34.2
Congestive heart failure* 15.8 10.9 28.9
Other cardiac 20.1 15.8 31.6
Cerebrovascular disease 10.8 8.9 15.8
Peripheral vascular
disease
9.4 9.9 7.9
❖Column % unless specified otherwise
*p < 0.05
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possible. Hymes et al, reported significant reductions in
AR-BSI to 0.67 per 100 patient-months with the intro-
duction of antimicrobial barrier caps [28]. A further
study by the CDC Dialysis BSI Prevention Collaborative,
demonstrated a sustained reduction in CVC-related
BSI’s from 2.26 to 1.08 events per 100 patient-months
using a bundle of BSI-preventative interventions [29].
These encouraging findings suggest that there is further
scope to reduce infection rates associated with CVC use
and emphasise the need for sustained quality improve-
ment initiatives.
Controversy currently exists as to whether tunnelled
dialysis catheters should be considered a satisfactory ac-
cess type for dialysis in older patients [30]. A lower rate
of complications in older patients would support this ap-
proach. In support of this hypothesis, Murea et al found
lower rates of catheter-related bacteraemia in patients
above 75 years versus younger patients (1.67 versus 5.99
events per 100 patient-months respectively, HR 0.33
(95% CI 0.20–0.55) [17], citing lower rates of nasal
colonisation, less sweating, and less mechanical stress
on the catheter as potential reasons. Wang et al
showed similar results [16]. However, several studies
have found no association between age and AR-BSIs
[18, 20–22]. Furthermore, mortality risks (infection-
related, cardiovascular-related, and all-cause) are
higher in patients on dialysis by CVC even in elderly
patients [31, 32]. The findings from our study are in
direct contrast with those of Murea et al in that eld-
erly patients experienced risks that were similar to
those of younger patients.
The most significant factor associated with increased
catheter-related BSIs in our population was site of the
tunnelled dialysis catheter. In univariate and multivari-
able analysis, femoral access was associated with a five-
fold increase in the rate of AR-BSI when compared to
non-femoral access. This observation may relate to
greater levels of skin contamination at the femoral area,
relatively more difficult access for cleaning and observa-
tion, or may relate to some patient characteristics such
Fig. 2 Rates of access-related bloodstream infections by access type. CVC: Central venous catheter, AVF: Arteriovenous fistula
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as vintage or poor health. Femoral access is known to
have higher rates of complications overall, including in-
fection and malfunction [16, 17]. Quality improvement
programs need to focus on this high-risk group of pa-
tients. We did not observe a difference in AR-BSI rates
between patients with and without diabetes in univariate
or multivariable analysis. Diabetes was found to be a risk
factor for bacteraemia in some [16, 18] but not all stud-
ies [17]. Similarly, gender did not have an effect on in-
fection rates, and this is consistent with multiple prior
studies [16–18].
Gram positive organisms were the predominant mi-
crobes from positive blood cultures in our cohort,
with only a smaller proportion of AR-BSIs attribut-
able to Gram negative (GN) organisms. Whereas
studies from the US, Brazil, Greece and Singapore re-
ported GN bacterial growth in 15 to 26% of positive
cultures [17, 18, 24, 27, 33, 34], GN bacteria were
identified in less than 5% of specimens in our study.
CoNS were identified in more than 60% of cases,
Fig. 3 Rates and rate ratios of access-related bloodstream infection events among patients receiving dialysis by tunnelled central venous catheter.
* p < 0.001. Multivariable model was adjusted for site of insertion, sex, diabetes and age group
Table 3 Types of organisms isolated in access-related
bloodstream infections
Organism Frequency (%)
Coagulase-negative Staphylococcus 61.7
Staphylococcus aureus 23.4
MSSA: 19.1%
MRSA: 4.3%
Beta-haemolytic Streptococci 4.3
Streptococcus parasanguinis 2.1
Enterococcus spp. 2.1
Vancomycin-resistant enterococci (VRE) 2.1
Proteus spp. 2.1
Poly-microbial 2.1
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which is a higher rate than compared to published lit-
erature. CoNS, despite being common constituents of
the normal flora of the skin, can be major nosocomial
pathogens and cause significant morbidity in patients
with CVCs [35]. Their spread is facilitated by poor
hand hygiene and inadequate disinfection or sterilisa-
tion of instruments or surfaces [35]. It is difficult
however to compare frequencies between different
studies because of different study inclusion and exclusion
criteria, and different definitions used. Our study also
highlights the high burden of these events on both the pa-
tient and the health system. Two bacteraemia-related fa-
talities were identified. The majority of patients with
AR-BSIs required hospitalisation, and catheter replace-
ment was required in more than 50% of patients.
A few limitations are worth mentioning. The study
was retrospective in design and thus not all known risk
factors were measured at baseline. Patients receiving dia-
lysis by CVC may be inherently different to those with
AVF. Our data did not enable us to characterise patients
beyond the variables used in our models. We did not
capture exit-site and tunnel infections in our study.
However, it should be noted that there is subjectivity in
the definition of these events and these may or may not
be associated with bacteraemia. The study reflects a sin-
gle centre experience, which may limit generalisability.
In addition, we did not differentiate between incident or
prevalent HD patients in our study. Therefore, we must
acknowledge we were unable to assess whether dialysis/
catheter vintage modifies the relationship with infection
risk in those with CVC’s. Finally, our unit’s policy on
management of access-related bacteraemia did not have
a standardised protocol to check for clearance of bacter-
aemia prior to or shortly after discontinuation of the
antimicrobial agent. This precluded conducting a reliable
comparison of clearance duration. These limitations,
however, were counterbalanced by several strengths.
First, our study included all chronic HD patients who re-
ceived dialysis at a large centre, and none of the patients
had missing data. Second, all microbiology test results
were available from a single central laboratory ensuring
consistency and reliability of reporting. This was of con-
cern in data reported from dialysis facilities in the US, as
blood cultures were analysed at several different labora-
tories, particularly for samples obtained after hospitalisa-
tion [24, 36]. We reported on BSI, a measure that is
based on an objective test, using standard definitions. Fi-
nally, the period of follow-up was long relative to other
published studies in the literature.
Conclusions
AR-BSI remain a significant complication particularly
among contemporary cohorts of patients undergoing
haemodialysis by tunnelled catheters. The risk is present
for all subgroups including the elderly. Access-related
bloodstream infections impose a huge burden on pa-
tients and on health systems. Active surveillance of
BSI linked to quality improvement initiatives should
remain an integral part of all dialysis programmes to
reduce catheter- associated infections and improve
patient outcomes.
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